Performing dual analysis with both liquid and tissue biopsies at metastatic diagnosis establishes a comprehensive baseline. This strategy helps differentiate between clonal and later-acquired mutations, enabling more accurate interpretation of subsequent ctDNA monitoring for resistance.
A large number of mutations detected in a cancer patient's blood (ctDNA) often originate from non-cancerous hematopoietic stem cells, a phenomenon called clonal hematopoiesis. This necessitates sophisticated filtering, such as matched normal sequencing, to distinguish tumor-derived mutations from this biological noise.
The failure of the PERSEVERA trial, which tested a similar drug in an unselected patient population, highlights the critical importance of SERENA-6's biomarker-driven approach. It proves that targeting only patients with the ESR1 mutation is necessary for efficacy, reinforcing the core value of precision oncology.
A key advantage of in-house genomic assays, like MSK's, is the ability to rapidly iterate based on direct feedback from practicing clinicians. This agile development cycle allows the test to be continuously updated with new genes and regions of interest, keeping it at the cutting edge of clinical and research needs.
The SERENA-6 trial tested a hypothesis rooted in evolutionary biology: intervening when a resistance mutation (ESR1) first appears in ctDNA, while the clone is small and less diverse, rather than waiting for clinical progression. This proactive approach aims to control resistance before it becomes dominant and harder to treat.
ODAC's critique of the SERENA-6 trial, focusing on immature overall survival (OS) data, contrasts sharply with previous landmark approvals like CDK4/6 inhibitors, which were approved without OS data. This suggests innovative, biomarker-adaptive trials may face a higher, potentially unfair, regulatory bar.